Peer-influenced content. Sources you trust. No registration required. This is HCN.
MDLinx
A Swedish case-control study identified a 21% increased risk of malignant lymphoma in individuals with tattoos compared to controls, prompting the need for further research into tattoo ink composition and potential long-term health effects.
Dermatology June 17th 2024
The New England Journal of Medicine
Secondary malignancies like indolent CD4+ CAR T-cell lymphoma can emerge after CAR T-cell therapy. This case highlights the importance of recognizing and thoroughly investigating these rare complications.
Hematology/Oncology June 17th 2024
The occurrence of second tumors, such as T-cell lymphomas, post-CAR T-cell therapy is rare. The study identifies Epstein-Barr virus and mutant clonal hematopoiesis as potential factors but finds no evidence of oncogenic retroviral integration, providing valuable insights for clinical practice.
A 73-year-old woman’s worsening rash and complex medical history culminated in a diagnosis of angioimmunoblastic T-cell lymphoma, underscoring the need for thorough diagnostic evaluation and aggressive treatment.
Dermatology May 22nd 2024
In a recent phase 3 trial, the addition of brentuximab vedotin to standard chemotherapy not only achieved a notable improvement in 3-year event-free survival rates for pediatric Hodgkin’s lymphoma patients but also maintained a comparable safety profile, underscoring the therapeutic potential of targeted treatments in this population.
Hematology/Oncology April 1st 2024
Clinical Advances in Hematology & Oncology
Epcoritamab represents a significant breakthrough in the treatment of Richter syndrome, showcasing promising results in patients who have exhausted other therapeutic avenues. Its unique bispecific action heralds a new era in hematologic malignancy management.
Hematology/Oncology March 18th 2024